Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Nasdaq Biotechnology Ishares ETF (NQ: IBB )

136.59 -0.58 (-0.42%)
Official Closing Price Updated: 4:15 PM EST, Feb 3, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,945,172
Open 136.85
Bid (Size) 136.13 (1)
Ask (Size) 137.50 (11)
Prev. Close 137.17
Today's Range 136.07 - 138.26
52wk Range 104.29 - 138.74
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
When Small Cap Biotechs Lose Momentum: Are You An Investor Or A Trader?
A few small cap biotechs lost momentum last week so now might be the time to take profits. But many of these stocks are favored because of their core technology and favored by funds; time to buy? 
Via Talk Markets
February PDUFA Catalysts Biotech Investors Must Know: Sanofi's Bleeding Disorder Drug, Regeneron's Twin Eylea Label Expansions, 3 Delayed Approvals And More
The year has started well for biopharma companies on the regulatory front, as most decisions handed out during January were positive. The Food and Drug Administration has already cleared four new... 
Via Benzinga

Performance

YTD
+5.04%
+5.04%
1 Month
+2.59%
+2.59%
3 Month
+5.82%
+5.82%
6 Month
+3.45%
+3.45%
1 Year
+3.76%
+3.76%

More News

Read More
Sector Shift Stalls Healthcare Stocks But Biotech Shows Gains In January
Via Talk Markets
What Are The Equities Market’s Warning Signs?
Via Talk Markets
Inflation, What Inflation?
Via Talk Markets
Global Stocks: Breaking Out?
Via Talk Markets
The 3 Best Biotech Stocks Under $1 to Buy for January
Via InvestorPlace
Longeveron Shares Surge Following FDA Decision on Biogen Alzheimer's Drug
Via Benzinga
SAVA, LLY, IBB: Why These Alzheimer's Related Stocks Are Volatile On Friday
Via Benzinga
Biogen's 2nd Alzheimer's Antibody, BeiGene's Cancer Drug Label Expansion, Adcom Test For Regeneron And More: January PDUFA Catalysts For Biotech Investors
Via Benzinga
Healthcare Portfolio Is Doing Well But Biotech Stocks Are Mired In Macro
Via Talk Markets
Tarsus Added to NASDAQ Biotechnology Index
From Tarsus Pharmaceuticals, Inc
Via Globe NewsWire
Small Caps Vs Large Caps: Who Is Leading?
Via Talk Markets
Meta Platforms, This Biotech ETF And These China Plays Are CNBC's 'Final Trades'
Via Benzinga
BriaCell’s Lead Candidate Bria-IMT™ Shows Promising Results For Advanced Breast Cancer Patients
Via TheNewswire.com
Topics Stocks
Exposures Product Safety US Equities
BriaCell’s Lead Candidate Bria-IMT™ Shows Promising Results For Advanced Breast Cancer Patients
Via News Direct
Exposures Product Safety
Mirati Plays Catch-Up With Amgen, Gilead's 2nd Try With AIDS Drug, Cytokinetics' Adcom Test And More: Key Nov FDA Decisions For Biotech Investors
Via Benzinga
BriaCell's Lead Candidate Bria-IMT™ Shows Promising Results For Advanced Breast Cancer Patients
Via Benzinga
Will The Dow Jones Continue Higher? Will The Nasdaq Follow?
Via Talk Markets
Uncertainty Grips Markets-On A Clear Day Maybe You Can See A Week Ahead
Via Talk Markets
Market Currents: Why Pick Stocks?
Via Talk Markets
Look Who’s Leading Now
Via Talk Markets
Provention Bio's Second Try, Apellis's Eye Disorder Drug Review, 3 Adcom Verdicts And More: November's Key PDUFA Catalysts Biotech Investors Must Know
Via Benzinga
Can Biotech Stocks Continue Rallying In This Bear Market?
Via Talk Markets
October Was Not So Scary After All - Things To Keep A Watch Out For
Via Talk Markets
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.